亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

医学 打开标签 彭布罗利珠单抗 间皮瘤 内科学 化疗 随机对照试验 肿瘤科 癌症 病理 免疫疗法
作者
Quincy S. Chu,Federica Perrone,Laurent Greillier,Wei Tu,Maria Carmela Piccirillo,Federica Grosso,Giuseppe Lo Russo,Marie Florescu,Manlio Mencoboni,Alessandro Morabito,Fabiana Letizia Cecere,Giovanni Luca Ceresoli,David E. Dawe,Paolo Andrea Zucali,Maria Pagano,John R. Goffin,Myriam Locatelli Sanchez,Cesare Gridelli,Gérard Zalcman,Xavier Quantin
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10419): 2295-2306 被引量:92
标识
DOI:10.1016/s0140-6736(23)01613-6
摘要

Summary

Background

Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum–pemetrexed would improve overall survival in patients with pleural mesothelioma.

Methods

We did this open-label, international, randomised phase 3 trial at 51 hospitals in Canada, Italy, and France. Eligible participants were aged 18 years or older, with previously untreated advanced pleural mesothelioma, with an Eastern Cooperative Oncology Group performance status score of 0 or 1. Patients were randomly assigned (1:1) to intravenous chemotherapy (cisplatin [75 mg/m2] or carboplatin [area under the concentration-time curve 5–6 mg/mL per min] with pemetrexed 500 mg/m2, every 3 weeks for up to 6 cycles), with or without intravenous pembrolizumab 200 mg every 3 weeks (up to 2 years). The primary endpoint was overall survival in all randomly assigned patients; safety was assessed in all randomly assigned patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02784171, and is closed to accrual.

Findings

Between Jan 31, 2017, and Sept 4, 2020, 440 patients were enrolled and randomly assigned to chemotherapy alone (n=218) or chemotherapy with pembrolizumab (n=222). 333 (76 %) of patients were male, 347 (79%) were White, and median age was 71 years (IQR 66–75). At final analysis (database lock Dec 15, 2022), with a median follow-up of 16·2 months (IQR 8·3–27·8), overall survival was significantly longer with pembrolizumab (median overall survival 17·3 months [95% CI 14·4–21·3] with pembrolizumab vs 16·1 months [13·1–18·2] with chemotherapy alone, hazard ratio for death 0·79; 95% CI 0·64–0·98, two-sided p=0·0324). 3-year overall survival rate was 25% (95% CI 20–33%) with pembrolizumab and 17% (13–24%) with chemotherapy alone. Adverse events related to study treatment of grade 3 or 4 occurred in 60 (27%) of 222 patients in the pembrolizumab group and 32 (15%) of 211 patients in the chemotherapy alone group. Hospital admissions for serious adverse events related to one or more study drugs were reported in 40 (18%) of 222 patients in the pembrolizumab group and 12 (6%) of 211 patients in the chemotherapy alone group. Grade 5 adverse events related to one or more drugs occurred in two patients on the pembrolizumab group and one patient in the chemotherapy alone group.

Interpretation

In patients with advanced pleural mesothelioma, the addition of pembrolizumab to standard platinum–pemetrexed chemotherapy was tolerable and resulted in a significant improvement in overall survival. This regimen is a new treatment option for previously untreated advanced pleural mesothelioma.

Funding

The Canadian Cancer Society and Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忧郁的涵雁完成签到 ,获得积分10
11秒前
38秒前
41秒前
lingrong发布了新的文献求助10
45秒前
M.发布了新的文献求助10
46秒前
M.完成签到,获得积分10
51秒前
53秒前
酷波er的应助被lingrong采纳,获得10
56秒前
佳言2009完成签到 ,获得积分10
1分钟前
负责的初柔完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被张阳采纳,获得10
1分钟前
1分钟前
1分钟前
yyzc6162发布了新的文献求助10
1分钟前
慕容杏子完成签到 ,获得积分10
1分钟前
1分钟前
MchemG的应助被科研通管家采纳,获得30
1分钟前
MchemG的应助被科研通管家采纳,获得30
1分钟前
1分钟前
1分钟前
清爽友蕊发布了新的文献求助10
1分钟前
张阳发布了新的文献求助10
1分钟前
在水一方的应助被amiee采纳,获得10
1分钟前
1分钟前
2分钟前
yyzc6162完成签到,获得积分10
2分钟前
amiee发布了新的文献求助10
2分钟前
忧虑的如雪完成签到,获得积分10
2分钟前
完美世界的应助被清爽友蕊采纳,获得10
2分钟前
犹豫擎苍完成签到,获得积分10
3分钟前
adefgv完成签到,获得积分10
3分钟前
3分钟前
fhjg完成签到,获得积分10
3分钟前
3分钟前
jtk完成签到,获得积分10
3分钟前
pwn完成签到,获得积分10
3分钟前
3分钟前
3分钟前
彭于晏的应助被科研通管家采纳,获得10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190127
求助须知:如何正确求助?哪些是违规求助? 9577239
关于积分的说明 21852194
捐赠科研通 7788458
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2560003
邀请新用户注册赠送积分活动 2482880